NEW YORK, April 2 – Dutch proteomics company Glaucus Proteomics has entered into a deal to gain access to Medarex’ and Genmab’s antibody technology in exchange for novel targets and shared rights to future therapeutic products, the companies said Monday.

“We provide the antibody technology to Glaucus and they are going to find diagnostics and research uses for antibodies. And using their antibody reporter matrix they will find new disease targets that we can make antibodies against,” Lisa Drakeman, CEO of Genmab, told GenomeWeb.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.